Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II Open-label Study of the Safety and Preliminary Efficacy of CTX-009 Administered Either as a Monotherapy or in Combination With CTX-471 in Patients With Recurrent Glioblastoma

NCT07392957 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07392957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II Open-label Study of the Safety and Preliminary Efficacy of CTX-009 Administered Either as a Monotherapy or in Combination With CTX-471 in Patients With Recurrent Glioblastoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 16, 2026
Completion date
June 30, 2031
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma